Cassava Shares Plunge 85% as Alzheimer Study Falls Short of Goals
Daily NewsInvesting.com -- Cassava Sciences, Inc., a biotechnology company focused on Alzheimer’s disease treatments, announced that its Phase 3 ReThink-ALZ study for the i...
Read More